![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 30, Issue 6, 613-615, June 2002
Is a Causal Factor
Responsible for Interindividual Differences in the Expression of
UDP-Glucuronosyltransferase 2B7 mRNA in Human Livers
Graduate School of Pharmaceutical Sciences, UDP-glucuronosyltransferase (UGT) 2B7 is one of the most important
UGT isozymes expressed in human livers. This enzyme is reported to show
more than 10-fold interindividual differences in its enzyme activities.
Thus, the amounts of UGT2B7 mRNA in 12 human livers were quantified by
quantitative reverse transcription-polymerase chain reaction. The
amounts of UGT2B7 mRNA in the subjects ranged from 0.22 to 2.63 copies/103 copies of
Hokkaido
University, Sapporo, Japan
(K.T., Y.Ta, H.Y., T.K.);
Department of Pharmacokinetics,
Dainippon Pharmaceutical Co.,
Ltd.
Osaka, Japan (Y.Te, T.F.);
Center for
Environmental and Occupational Health,
University of Kansas
Medical Center,
Kansas City, Kansas (A.P.)
-actin. A novel point mutation
(
253G to A) found in this study did not affect the level of UGT2B7
mRNA in the subjects. To clarify a causal factor(s) determining the
expression level of UGT2B7 mRNA, we examined the correlation between
the amounts of mRNAs for UGT2B7 and hepatocyte nuclear factor
(HNF)-1
, which regulates the expression of UGT2B7
gene. HNF-1 mRNA was expressed at a level ranging from 2.99 to 24.76 copies/106 copies of -actin in the subjects. The amounts
of mRNAs for UGT2B7 expressed in these individual liver samples were
highly associated with the amount of mRNA for HNF-1
(r = 0.786, p = 0.002),
suggesting that HNF-1 is a factor limiting the expression of UGT2B7
mRNA and a causal factor responsible for an interindividual difference in human livers.
This article has been cited by other articles:
|
|
 |
|
  H. S. Smith Opioid Metabolism Mayo Clin. Proc., July 1, 2009; 84(7): 613 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ross, J. Riley, C. Quigley, and K. I. Welsh Clinical Pharmacology and Pharmacotherapy of Opioid Switching in Cancer Patients Oncologist, July 1, 2006; 11(7): 765 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Matsumura, T. Saito, Y. Takahashi, T. Ozeki, K. Kiyotani, M. Fujieda, H. Yamazaki, H. Kunitoh, and T. Kamataki Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene Mol. Pharmacol., February 1, 2004; 65(2): 326 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Hesse and M. H. Court Quantitation of CYP2B6, Constitutive Androstane Receptor, and Pregnane X Receptor mRNA levels Drug Metab. Dispos., May 1, 2003; 31(5): 685 - 685. [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. Iyer, M. N. Ho, W. M. Shinn, W. W. Bradford, M. J. Tanga, S. S. Nath, and C. E. Green Glucuronidation of 1'-Hydroxyestragole (1'-HE) by Human UDP-Glucuronosyltransferases UGT2B7 and UGT1A9 Toxicol. Sci., May 1, 2003; 73(1): 36 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Toide, H. Yamazaki, R. Nagashima, K. Itoh, S. Iwano, Y. Takahashi, S. Watanabe, and T. Kamataki Aryl Hydrocarbon Hydroxylase Represents CYP1B1, and not CYP1A1, in Human Freshly Isolated White Cells: Trimodal Distribution of Japanese Population According to Induction of CYP1B1 mRNA by Environmental Dioxins Cancer Epidemiol. Biomarkers Prev., March 1, 2003; 12(3): 219 - 222. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
